First Trimester Metformin in Polycystic Ovary Syndrome Patients with History of Recurrent Early Pregnancy Loss: Randomized Controlled Trial | ||||
| Al-Azhar International Medical Journal | ||||
| Volume 2023, Issue 1, January 2023 | ||||
| DOI: 10.58675/2682-339X.1975 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Farid Ibrahim Hassan; Muhamed Ahmed Abdelmoaty; Ahmed Hamdy Muhammed Saad | ||||
| Department of Obstetrics and Gynecology, Faculty of Medicine for boys, Al-Azhar University, Cairo, Egypt. | ||||
| Abstract | ||||
| Background: Women with polycystic ovarian syndrome (PCOS) who take metformin throughout their pregnancies have lower rates of miscarriage, labour, and foetal development restriction. Positive benefits of metformin on insulin sensitivity, plasma glucose concentration, and lipid profile have been shown in patients with polycystic ovary syndrome. Aim and objectives: to the disparity in the occurrence of miscarriage between two patient cohorts who will get or not receive Metformin in the first trimester, to determine the efficacy of Metformin in preventing early pregnancy loss in pregnant patients with PCOs. Subjects and methods: This was a randomised controlled trial that was conducted on 100 recently pregnant PCO patients at the Department of Obstetrics and Gynecology, Faculty of Medicine, Al-Azhar University, from January 2022 to November 2022. Result: Group A had a much lower EPL rate than Group B. Conclusion: In conclusion, Pregnant women with polycystic ovary syndrome who took metformin consistently during the first trimester had significantly lower rates of miscarriage. Patients accepted it well and experienced little negative effects. However, more research is needed to determine its impact on subsequent pregnancy problems and foetal outcomes, | ||||
| Keywords | ||||
| early pregnancy loss; Insulin Resistance; Metformin; polycystic ovary syndrome | ||||
|
Statistics Article View: 13 |
||||
